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essential for its function. eIF5A is also acetylated, but the role of that modiﬁcation is unknown. Here,
we report that acetylation regulates the subcellular localization of eIF5A. We identiﬁed PCAF as the
major cellular acetyltransferase of eIF5A, and HDAC6 and SIRT2 as its major deacetylases. Inhibition
of the deacetylases or impaired hypusination increased acetylation of eIF5A, leading to nuclear accu-
mulation. As eIF5A is constitutively hypusinated under physiological conditions, we suggest that
reversible acetylation plays a major role in controlling the subcellular localization of eIF5A.
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eIF5A is a small (17 KDa) acidic protein that is essential for cell
proliferation in many eukaryotes. Mammals have two paralogs,
eIF5A1 and eIF5A2. eIF5A1 is ubiquitously expressed in all tissues
[1–3] and is modiﬁed post-translationally with an unusual amino
acid, hypusine [Ne-(4-amino-2-hydroxybutyl)lysine] [4]. Hypusine
is synthesized from the polyamine spermidine in two consecutive
enzymatic steps: ﬁrst, deoxyhypusine synthase (DHS) catalyzes the
transfer of the aminobutyl moiety from spermidine to a speciﬁc ly-
sine residue (Lys50 in human eIF5A) to form the deoxyhypusine
intermediate, which is ultimately hydroxylated by deoxyhypusine
hydroxylase (DOHH) to produce active hypusinated eIF5A [5].
eIF5A and its hypusine modiﬁcation are essential in cellular phys-
iology: hypusination mutants exhibit slowed cell growth in mam-
mals [6]; in yeast, a hypusination site mutant (K51R) fails to rescuechemical Societies. Published by E
aboratory, RIKEN Advanced
0198, Japan. Fax: +81 48 462the eIF5A knockout [3]. Although eIF5A is evidently essential for
eukaryotic cell proliferation [2,7,8], its precise function has re-
mained unknown. eIF5A was originally identiﬁed, along with other
initiation factors, from high-salt washes of rabbit reticulocytes ly-
sate ribosomes [9], and was shown to stimulate methionyl-puro-
mycin synthesis [10]; therefore, eIF5A was considered to be a
translational initiation factor. However, recent ﬁndings suggest
that it plays a role in translation elongation [11] and other aspects
of RNA metabolism such as RNA export [12,13].
The subcellular localization of eIF5A and its involvement in nu-
clear export have remained controversial. eIF5A was initially dem-
onstrated to be localized at the nuclear pore complex, where it is
involved in Rev-mediated nuclear export of unspliced HIV-1
mRNAs [12]. However, Shi et al. showed that eIF5A is cytoplasmic
in a variety of cell types, and that HIV-1 Rev overexpression does
not affect its cellular distribution [14]. Subsequently, Rosorius
et al. demonstrated that eIF5A undergoes nucleo-cytoplasmic shut-
tling, and proposed that CRM1 acts as its nuclear export factor [15].
Although eIF5A lacks a conventional nuclear import signal, exper-
iments with GFP-tagged truncated eIF5A suggested that the 19
N-terminal residues are responsible for eIF5A nuclear localization
[16]. eIF5A regulates diverse cellular processes, including induc-
tion of p53-dependent apoptosis and cytokine-mediated islet b celllsevier B.V. All rights reserved.
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nucleus. Recently, Lee et al. demonstrated that exogenously pro-
duced eIF5A is primarily expressed as an unhypusinated precursor,
and can only be hypusinated when co-expressed with DHS and
DOHH. Moreover, unhypusinated GFP-eIF5A is primarily localized
in the nucleus, whereas the hypusinated form is cytoplasmic, sug-
gesting that hypusination determines the subcellular distribution
of eIF5A [19]. However, because hypusination occurs on almost
all eIF5A proteins, co-translationally [20] and irreversibly, hypusi-
nation seems unlikely to be responsible for the dynamic regulation
of nucleo-cytoplasmic transport under physiological conditions.
eIF5A residues K47 and K68 are post-translationally modiﬁed by
acetylation [20,21]. The crystal structure of human eIF5A consists
of two domains of predominantly b-sheet character [22]. The acet-
ylation and hypusination sites (i.e. K47 and K50, respectively) are
in close proximity on a disordered loop structure, the hypusine
loop, in the N-terminal domain. The positive charge at K47 is
essential for eIF5A activity, suggesting that acetylation at this posi-
tion negatively regulates eIF5A function in protein synthesis [23].
However, the role of eIF5A acetylation in other functions remains
elusive.
In this study, we found that the acetylated form of eIF5A is pri-
marily enriched in the nucleus, whereas unacetylated eIF5A is pri-
marily cytoplasmic; this distinction is even more pronounced in
the presence of histone deacetylase (HDAC) inhibitors. These re-
sults suggest that acetylation acts as a molecular switch for eIF5A,
allowing it to exert distinct functions in the cytoplasm and nucleus.
2. Materials and methods
2.1. Compounds, cell culture and transfection
Tricostatin A (TSA) and nicotinamide (NA) were purchased from
Wako Chemicals. GC7 was purchased from BIOSEARCH TECHNOL-
OGIES, INC., SCOP402 was kindly provided by Dr. Norikazu Nishino
(Kyushu Institute of Technology, Japan). All compounds were pre-
pared as stock solutions in dimethyl sulfoxide (DMSO) and stored
at 20 C. 293T and HeLa cells were transiently transfected with
expression vectors using the FuGENE HD reagent (Roche) and
the Lipofectamine™ LTX reagent (Invitrogen), respectively. RNAi
oligos used in this study were obtained from Dharmacon, with
the exception of the eIF5A and HDAC1 oligos, which were obtained
from Nippon Gene. All sequence information of siRNA oligos is de-
scribed in Supplemental Table 1.
2.2. Plasmids construction
The cDNA encoding human eIF5A was PCR-ampliﬁed from a hu-
man brain cDNA library and sub-cloned into either GFP-pEGFP (BD
Biosciences) or to the C-terminus of Flag-tag in pcDNA3 (Invitro-
gen). Plasmids for expression of GFP-eIF5A and Flag-eIF5A mutant
proteins (K47R, K47Q, K50R, and K47,50R) were generated by site-
directed mutagenesis using primer sets containing the desired
mutations. DNA encoding human DHS was PCR-ampliﬁed from a
human brain cDNA library and sub-cloned into pcDNA3-Flag. The
pcEFL-DOHH construct was kindly provided by Dr. Myung Hee
Park (National Institute of Health, USA); the coding sequence was
PCR-ampliﬁed and sub-cloned into the pcDNA3-Myc vector.
2.3. Antibodies and immunoblotting
A rabbit polyclonal antibody against acetylated eIF5A was
raised using an acetylated eIF5A peptide (VDMSTSK(Ac)TGKHGHC)
with the aid of the Support Unit for Bio-material Analysis and Ani-
mal Resources Development at the RIKEN BSI Research Resources
Center (RRC). A mouse monoclonal antibody against hypusinatedeIF5A was raised using a hypusinated eIF5A peptide
(STSKTGK(Hyp)HGHAKC). Mouse monoclonal anti-Flag M2, anti-
a-tubulin (B-5-1-2), and anti-Ac-a-tubulin (6-11B-1) antibodies
were purchased from Sigma. Monoclonal anti-c-Myc (9E10) and
monoclonal anti-eIF5A antibodies were obtained from Santa Cruz
Biotechnology and BD Bioscience, respectively. Rabbit polyclonal
anti-CBP, anti-PCAF, anti-GCN5, anti-SIRT1, and anti-SIRT2 anti-
bodies were purchased from Cell Signaling Technology. Immuno-
blotting was performed using whole cell lysates, prepared by
collecting washed cells directly in 1 SDS–PAGE sample loading
buffer and heating at 95 C for 5 min. Equal volumes of each whole
cell lysate was resolved by SDS–PAGE and transferred to a polyvi-
nylidene diﬂuoride membrane (Millipore) by electroblottting.
Membranes were incubated with primary and secondary antibod-
ies; immune complexes were detected using the Immobilon™
Western Chemiluminescent HRP substrate (Millipore); and lumi-
nescence was analyzed using a LAS-3000 image analyzer (GE
Healthcare).
2.4. Immunostaining and ﬂuorescence microscopy
Cells grown on coverslips were ﬁxed in 4% paraformaldehyde
for 15 min and permeabilized in 0.2% Triton X-100 in PBS (PBT).
Fixed cells were blocked with 5% normal goat serum in 0.1% PBT
for 15 min and incubated with primary antibodies against eIF5A
(1:200 dilution), Ac-eIF5A (1:100), Flag (1:500), or Myc (1:500)
for 1–2 h followed by the Alexa Fluor 594, Alexa Fluor 488, or Alexa
Fluor 350 secondary antibodies (Invitrogen) for 20 min. Slides were
mounted with mounting medium (Vector Laboratories), and
images were taken using a Delta Vision Microscope (SEKI Techno-
tron Corp.).
2.5. In vitro histone acetyltransferases (HATs) assay
Recombinant His-tagged eIF5A was puriﬁed as described previ-
ously [24]. In vitro HAT assays were performed as described previ-
ously [24] with minor modiﬁcations: brieﬂy, 8 lg of His-eIF5A was
incubated with 8.5 lg of puriﬁed Flag-PCAF in the presence of
0.33 mM acetyl CoA. The reaction was performed at 37 C for 1 h.
The samples were mixed with reducing/loading buffer and re-
solved by SDS–PAGE on 13% polyacrylamide gels followed by
immunoblotting with the indicated antibodies.
3. Results and discussion
3.1. Hypusination inhibits acetylation
Using an anti-acetylated lysine (Ac-Lys) antibody and radioac-
tively labeled spermidine, Lee et al. observed that co-transfection
with DHS and DOHH enables hypusination of eIF5A exogenously
expressed in mammalian cells; furthermore, unhypusinated eIF5A
expressed in the absence of DHS and DOHH is heavily acetylated at
K47 but is dramatically deacetylated upon hypusination, suggest-
ing crosstalk between hypusination and acetylation [19]. We ﬁrst
conﬁrmed these observations using a newly developed anti-acety-
lated eIF5A (Ac-eIF5A), and an anti-hypusinated eIF5A (Hyp-eIF5A)
antibody. Exogenously expressed eIF5A could be hypusinated only
when co-expressed with DHS and DOHH (Fig. 1A). In addition, DHS
and DOHH expression reduced the acetylation at K47 (Fig. 1A). The
speciﬁcity of the antibodies was conﬁrmed by detecting acetyla-
tion and hypusination of K47R and K50R mutants as well as
wild-type eIF5A overexpressed in 293T cells with or without
DHS/DOHH (Fig. 1B). In the absence of DHS and DOHH, wild-type
Flag-eIF5A was heavily acetylated, but the acetylation signal was
completely lost in K47R, indicating that the antibody can speciﬁ-
cally recognize eIF5A acetylated at K47. The hypusination signal
BC
A
Fig. 1. Interplay between eIF5A acetylation and hypusination. (A, B) 293T cells were transfected with FLAG-eIF5A wild-type (WT), acetylation site (K47R), or hypusination site
(K50R) mutants in the presence or absence of pcDNA3-hDHS and pcDNA3-hDOHH. Whole-cell lysates were immunoblotted with the indicated antibodies. The blots show
exogenously expressed eIF5A. (C) Whole-cell lysates from HeLa cells treated for 16 h with different concentrations of the DHS inhibitor GC7 were immunoblotted with the
indicated antibodies.
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ence of DHS and DOHH, but not in the K50R mutant lacking the
hypusination site. Hypusination of the K47R mutant, which is
defective in acetylation, suggests that acetylation is not required
hypusination. To further observe the relationship between hypusi-
nation and acetylation, we treated HeLa cells with different
concentrations of GC7, a DHS inhibitor, for 16 h. Immunoblot
analysis showed that GC7 inhibited eIF5A hypusination at a con-
centration as low as 2 lM. While the eIF5A acetylation level was
low in cells treated with GC7 at a low concentration (0.5 lM), it
was dramatically increased by 2 lM or higher concentrations,
conﬁrming that hypusination negatively regulates acetylation
(Fig. 1C). Endogenous eIF5A in the steady state is poorly acetylated
because eIF5A is fully hypusinated in the absence of GC7 (Fig. 1C).
Because crystal structure analysis revealed that the two lysine
residues for acetylation and hypusination are closed [22], hypusi-
nation may hinder the access of the eIF5A acetyltransferase, PCAF
(see below).
3.2. Identiﬁcation of HATs and HDACs regulating eIF5A acetylation
status
To identify the cellular acetyltransferase responsible for eIF5A
acetylation, we next performed siRNA-mediated knockdown
experiments using 293T cells (Fig. 2A). Of four acetyltransferases
tested, only PCAF knockdown signiﬁcantly reduced the acetylation
level of endogenous eIF5A. Furthermore, in an in vitro HAT assay
using bacterially produced recombinant eIF5A, we found that PCAF
indeed acetylates eIF5A in an acetyl-CoA-dependent manner
(Fig. 2B). To identify the class of HDACs involved in deacetylation
of eIF5A, we treated 293T cells with three HDAC inhibitors of dif-
fering speciﬁcity: TSA, NA, and SCOP402. TSA inhibits all class I/II
enzymes, whereas NA inhibits class III; SCOP402 inhibits class I/II
enzymes except HDAC6 [25]. Immunoblot analysis of the cell ly-
sates collected after 16 h incubation with the HDAC inhibitors
showed that acetylated eIF5A was increased in both TSA- and
NA-treated cells but not in SCOP402-treated cells (Fig. 2C). Because
the only difference in target enzyme speciﬁcity between TSA and
SCOP401 is HDAC6 inhibition, we conclude that at least HDAC6
is involved in deacetylation of eIF5A. The acetylation signal was
signiﬁcantly enhanced in cells treated with both TSA and NAsimultaneously, suggesting that a class III HDAC in addition to
HDAC6 is also involved in the eIF5A deacetylation. Importantly,
the level of eIF5A hypusination was not changed in response to
treatment with HDAC inhibitors (Fig. 2C), suggesting that acetyla-
tion does not affect its hypusination. Next, we expressed ten major
cellular deacetylase enzymes together with Flag-eIF5A in 293T
cells (Fig. 2D, S1A). Only overexpression of HDAC6 or SIRT2, but
not their catalytically dead mutants, signiﬁcantly reduced the acet-
ylation level of eIF5A. Consistent with this, the acetylation level of
endogenous eIF5A was greatly increased by HDAC6 and SIRT2
knockdown in 293T cells (Fig. 2E), indicating that these enzymes
actually work as deacetylases under physiological conditions.
Additionally, SIRT1 overexpression slightly but reproducibly re-
duced eIF5A acetylation. Indeed, both recombinant SIRT1 and
SIRT2 catalyzed the deacetylation of eIF5A in an in vitro deacetyl-
ase assay (Fig. S1B–C). However, the SIRT1 knockdown failed to in-
crease endogenous eIF5A acetylation in 293T cells (Fig. 2E). These
results indicate that HDAC6 and SIRT2 are the major cellular
deacetylases of eIF5A.
3.3. Effect of acetylation and hypusination on subcellular distribution
of eIF5A
Lee et al. reported that hypusination is important for the local-
ization of eIF5A to the cytoplasm, where translation occurs [19]. In
general, reversible acetylation plays a role in regulating protein–
protein interactions and subcellular localization. As the acetylation
site is located within a loop close to the hypusination site (K50), it
seemed possible that eIF5A acetylation plays some role in the sub-
cellular localization of eIF5A. Therefore, we investigated the sub-
cellular localization of acetylated species of endogenous eIF5A by
indirect immunoﬂuorescence. Although total eIF5A was primarily
cytoplasmic in nature, acetylated eIF5A was predominately local-
ized to the nucleus (Fig. 3A). The ﬂuorescent signals obtained with
eIF5A and Ac-eIF5A antibodies are speciﬁc, because these signals
were diminished, respectively, by eIF5A knockdown and by com-
petition with the acetylated peptide used as the epitope (Fig. 3A).
Furthermore, treatment with either HDAC inhibitors (TSA/NA) or
DHS inhibitor (GC7) induced a dramatic shift of subcellular distri-
bution from primarily cytoplasmic to nuclear (Fig. 3B). These re-
sults clearly demonstrate that cytoplasmic eIF5A is not
B C
D
A
E
Fig. 2. Identiﬁcation of the acetyltransferases (HATs) and deacetylases (HDACs) of eIF5A. (A) Effects of siRNA mediated-knockdown of different HATs on eIF5A acetylation in
293T cells. 293T cells were transfected with siRNA oligos against the indicated HATs for 72 h, and whole-cell lysates were immunoblotted with the indicated antibodies. (B) In
vitro acetylation of eIF5A by recombinant PCAF. Recombinant His-tagged eIF5A was incubated with recombinant PCAF in the presence or absence of acetyl-CoA; the reaction
mixture was immunoblotted with the indicated antibodies. (C) Effects of HDAC inhibitors on eIF5A acetylation. Whole-cell lysates from 293T cells treated with TSA, NA, a
mixture of TSA and NA, or SCOP402 were immunoblotted with the indicated antibodies. (D) Effects of overexpression of HDACs on eIF5A acetylation. Whole-cell lysates from
293T cells overexpressing the indicated ﬂag tagged class I/II HDACs or myc tagged class III HDACs were immunoblotted with the indicated antibodies including the mixture of
anti-ﬂag and anti-myc antibodies (Flag/Myc). An arrowhead and a block arrow indicate exogenous and endogenous eIF5A, respectively (E) Effects of siRNA-mediated
knockdown of different HDACs on eIF5A acetylation in 293T cells. 293T cells were transfected with siRNA oligos against the indicated HDACs for 72 h; whole-cell lysates were
immunoblotted with the indicated antibodies.
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ylation directs nuclear localization.
Next we tested whether eIF5A K47 acetylation is indeed impor-
tant for controlling the subcellular localization of eIF5A, by express-
ing GFP-eIF5A and its mutants. As shown in Fig. 4A, unhypusinated
GFP-eIF5A expressed in the absence of DHS/DOHH tended to local-
ize to the nucleus. On the other hand, both wild-type eIF5A and a
mutant incapable of being acetylated (K47R) were successfully
localized to the cytoplasm when hypusinated by DHS/DOHH
(Fig. 4A). Importantly, the subcellular distribution of a mutant
mimicking acetylation (K47Q)was constitutively nuclear even after
hypusination by DHS/DOHH (Fig. 4A–B), suggesting that acetyla-
tion interferes with the eIF5A nuclear export. Similarly, the K50R
mutant, which is unhypusinated but heavily acetylated, also accu-
mulated in the nucleus. The K47,50R mutant, which can be neither
acetylated nor hypusinated, was also localized to the nucleus
(Fig. 4A–B). These results indicate that cytoplasmic localization of
eIF5A requires not only hypusination but also hypoacetylation.
Various groups studying the subcellular localization of eIF5A
have reported somewhat inconsistent results. For instance, Xiao
et al. reported that eIF5A is cytoplasmic and co-localizes with theendoplasmic reticulum in multiple mammalian cell lines [26]. In
contrast, Rosorius et al. proposed that eIF5A undergoes nucleo-
cytoplasmic shuttling and co-localizes with the nuclear pore com-
plex; these authors identiﬁed CRM1 as the corresponding nuclear
export factor [15]. Jao et al. also suggested that eIF5A enters the
nucleus through passive diffusion and may be exported from the
nucleus in a CRM1-dependent manner [27]. On the other hand,
other groups showed that exportin 4, an importin b family recep-
tor, is responsible for the nuclear export of eIF5A [13,28]. Recently
Lee et al. reported that compared to fully hypusinated cytoplasmic,
endogenous eIF5A, exogenously expressed eIF5A lacking hypusina-
tion tends to localize in the nucleus, but can be relocalized to the
cytoplasm when fully hypusinated [19]. Compared to the stable
hypusine modiﬁcation, acetylation is reversible and may play an
important role in regulating eIF5A cellular activity by altering the
conformation of the hypusine loop or eIF5A’s afﬁnity for nuclear
transport factors. Thus, control of subcellular localization of eIF5A
appears to be dependent more on acetylation than on hypusination
under the physiological condition. Our data indicate that co-trans-
lationally hypusinated eIF5A is acetylated by PCAF and deacety-
lated by HDAC6 and SIRT2, which facilitates nucleo-cytoplasmic
BA
Fig. 3. Subcellular distribution of endogenous acetylated eIF5A. (A) HeLa cells treated with either control (upper panels) or eIF5A (lower panels) siRNA oligo were
immunostained with anti-eIF5A antibody. Subcellular distribution of acetylated eIF5A was determined by immunostaining with anti-Ac-eIF5A antibody (upper panels);
speciﬁcity of the antibody was determined using competition with Ac-eIF5A peptide (lower panels). (B) Subcellular distributions of total and acetylated eIF5A in HeLa cells
treated with DMSO, TSA and NA, or GC7 were determined by immunoblotting with anti-eIF5A and anti-Ac-eIF5A antibodies.
BA
Fig. 4. Subcellular distributions of acetylation and hypusination mutants of GFP-fused eIF5A. (A) HeLa cells were transfected with the indicated GFP-eIF5A constructs in the
presence or absence of myc-hDOHH and Flag-hDHS; and immunostained with anti-myc and anti-FLAG antibodies in order to detect hDOHH and hDHS, respectively. (B)
Acetylation and hypusination status of modiﬁcation-site mutants of eIF5A. Whole-cell lysates of HeLa cells overexpressing the indicated GFP-fused eIF5A constructs with or
without hDHS and hDOHH were immunoblotted with the indicated antibodies.
3240 M. Ishfaq et al. / FEBS Letters 586 (2012) 3236–3241shuttling of eIF5A. Although the nuclear function of eIF5A is still
unclear, the evolutionarily conserved acetylation occurring near
the site of hypusination may regulate its nuclear localization and
its function in the nucleus.
4. Conclusion
We have elucidated the enzymes responsible for determining
the acetylation status of eIF5A K47: PCAF performs acetylation,
while HDAC6 and SIRT2 perform deacetylation. Our results suggest
that eIF5A acetylation status regulates its subcellular localization.
This knowledge will enable us to study the possible functional roleof this important protein in the nuclear compartment under phys-
iological conditions.
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